Results 101 to 110 of about 11,390 (145)

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer. [PDF]

CA Cancer J Clin
Singareeka Raghavendra A, Damodaran S, Barcenas CH, Fuqua SA, Layman RM, Tripathy D.   +5 more
europepmc   +1 more source

Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review. [PDF]

Transl Breast Cancer Res
Stravodimou A, Voutsadakis IA.
europepmc   +1 more source

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. [PDF]

NPJ Breast Cancer
House NC, Chen MM, Khazaei S, Brown V, Ramsden P, Peng DH, Moore S, Yuan L, Wu R, Wang F, Luo L, Feng N, Bristow CA, Yap TA, Keyomarsi K, Marszalek JR, Ribich S, Rinne ML, Muthuswamy LB, Faia KL.   +19 more
europepmc   +1 more source

Imlunestrant in ER+ advanced breast cancer - bridging innovation and clinical reality. [PDF]

Ann Med Surg (Lond)
Khalid A, Inayat M, Khalid M.
europepmc   +1 more source

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Lloyd MR, Weipert CM, Ali A, Solomon SR, Saha J, Lipsyc-Sharf MD, Hamilton EP, Kalinsky K, Brufsky AM, Bardia A, Zhang N, Wander SA.   +11 more
europepmc   +1 more source

Navigating Treatment Sequencing in Advanced HR+/HER2- Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies. [PDF]

Int J Mol Sci
Narvaez DP, Cescon DW.
europepmc   +1 more source

The Effect of Bazedoxifene and Fulvestrant for Preventing Ovarian Hyperstimulation Syndrome: An Experimental Study. [PDF]

J Clin Med
Ozdemir F, Acmaz G, Yay AH, Mat OC, Zararsiz GE, Acmaz B, Muderris I, Muhtaroglu S, Karakas E, Inanc M.   +9 more
europepmc   +1 more source

Cyclin-Dependent 4/6 Kinase Inhibitors for Treatment of HER2-Positive Breast Cancer: 2026 Update. [PDF]

Cancers (Basel)
O'Sullivan CC.
europepmc   +1 more source

Toxicity profiles of cyclin-dependent kinase 4/6 inhibitors: safety analysis from clinical trials and the FDA adverse event reporting system. [PDF]

Front Oncol
Zhou J, Lin X, Wang S, Xie M, Hu X, Cai J.   +5 more
europepmc   +1 more source

Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2- mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC). [PDF]

Curr Oncol
Median MD, Antone NZ, Volovăț S, Mazilu L, Negru ȘM, Curcă RO, Niță A, Pătru RI, Ungureanu A, Lupu V, Oprean CM.   +10 more
europepmc   +1 more source